NeoGenomics moves to Nasdaq

FORT MYERS — The shares of cancer-testing firm NeoGenomics recently started trading on the Nasdaq Capital Market, boosting its exposure to institutional investors.

The shares now trade under the symbol NEO and the recent share price was $3. Previously, NeoGenomics shares traded over-the-counter under the symbol NGNM.

“The transition to the Nasdaq Capital Market is a significant milestone for NeoGenomics and reflects the strong revenue and operating income growth we have achieved over the last several years,” says Douglas VanOort, the company's chairman and CEO, in a statement. “We believe this move will increase the visibility and liquidity of our shares in the market, and we are honored to join the long list of prestigious companies already traded on Nasdaq.”